PARP1 and central nervous system cancer: To determine if PARP inhibition sensitized gliomas to TMZ, we treated 15 low-passage patient-derived lines established and grown as spheres in neural stem cell media [27] (Table 1) with TMZ, ABT-888, or the combination.